Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer

The advent of personalized therapy for non-small-cell lung carcinoma (nsclc) has improved patient outcomes. Selection of appropriate targeted therapy for patients with nsclc now involves testing for multiple biomarkers, including EGFR. EGFR mutation status is required to optimally treat patients wit...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Curr Oncol
Prif Awduron: Cheema, P.K., Gomes, M., Banerji, S., Joubert, P., Leighl, N.B., Melosky, B., Sheffield, B.S., Stockley, T., Ionescu, D.N.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Multimed Inc. 2020
Pynciau:
Practice Guideline
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755440/
https://ncbi.nlm.nih.gov/pubmed/33380864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.7297
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg